Answers are grounded in this paper and cite their sources.
mRNA therapeutics are being formulated for cancer immunotherapy, cell therapy and gene therapy. Nevertheless, these therapeutics remain constrained due to manufacturing expenses, bioavailability and stability. Artificial intelligence (AI) and machine learning (ML) accelerate development through in silico validation and virtual screening. These allow formulation optimization, library screening, binding prediction, and rapid analysis; reducing time duration and labor. Yet, data heterogeneity across nanoparticle repositories and mRNA databases due to poor data standards, model inconsistency and literature gaps decreases the ease of clinical translation. Thus, generating standardized datasets connecting with LNP parameters with mRNA features, validating predictions throughout the therapeutic process and creating models linking molecular and systemic scales is essential, provided that the integration of nanomedicine, AI/ML and mRNA aids to formulate precise, personalized and economical therapeutics that are suitable for large scale implementation.
No takes yet. Share an insight, caveat, or question.
Jirage et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: